Jenna L. Talarico

Jenna L. Talarico serves as an Acquisition Specialist responsible for managing the full lifecycle of procurement actions within a specialized federal program focused on biological product manufacturing. Her role centers on ensuring compliance with federal acquisition regulations while delivering mission-critical biological therapeutics and related production capabilities. She oversees the development of solicitation documents, evaluation of technical proposals, contract award recommendations, and post-award administration, aligning acquisitions with national health security objectives. Talarico’s portfolio is exclusively dedicated to complex, high-regulatory-barrier procurements requiring deep scientific and manufacturing expertise. While specific contractor relationships are not currently identifiable in available data, her procurement patterns indicate consistent engagement with manufacturers possessing cGMP certification, FDA-registered facilities, and validated production processes. She typically works with a select group of qualified industry vendors capable of meeting stringent quality control and supply chain integrity requirements, fostering long-term partnerships built on technical reliability and regulatory compliance. Talarico’s contracting activity reflects a 100% preference for open competition with no set-asides, indicating a focus on technical capability and production scale over socioeconomic classifications. This approach suggests a prioritization of mission-critical delivery timelines and manufacturing capacity over targeted small business participation, though she remains compliant with all federal socioeconomic contracting mandates. Her procurement focus is entirely concentrated on NAICS 325414 — Biological Product (except Diagnostic) Manufacturing — encompassing the acquisition of biologics, vaccines, monoclonal antibodies, and other therapeutic substances requiring controlled production environments. She possesses specialized expertise in evaluating GMP compliance, cold chain logistics, sterile manufacturing, and biosafety protocols, making her a key steward of the nation’s biopharmaceutical supply chain.